SARS-CoV-2 Spike S1 Protein Antibody (1035206) [Unconjugated]

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

SARS-CoV-2, which causes the global pandemic coronavirus disease 2019 (Covid-19), belongs to a family of viruses known as coronaviruses that are commonly comprised of four structural proteins: Spike protein(S), Envelope protein (E), Membrane protein (M), and Nucleocapsid protein (N) (1). SARS-CoV-2 Spike Protein (S Protein) is a glycoprotein that mediates membrane fusion and viral entry. The S protein is homotrimeric, with each ~180-kDa monomer consisting of two subunits, S1 and S2 (2). In SARS-CoV-2, as with most coronaviruses, proteolytic cleavage of the S protein into two distinct peptides, S1 and S2 subunits, is required for activation. The S1 subunit is focused on attachment of the protein to the host receptor while the S2 subunit is involved with cell fusion (3-5). Based on structural biology studies, the receptor binding domain (RBD), located in the C-terminal region of S1, can be oriented either in the up/standing or down/lying state (6). The standing state is associated with higher pathogenicity and both SARS-CoV-1 and MERS can access this state due to the flexibility in their respective RBDs. A similar two-state structure and flexibility is found in the SARS-CoV-2 RBD (7). Based on amino acid (aa) sequence homology, the SARS-CoV-2  S1 subunit has 65% identity with SARS-CoV-1 S1 subunit,  but only 22% homology with the MERS S1 subunit. The low aa sequence homology is consistent with the finding that SARS and MERS bind different cellular receptors (8). The S Protein of the SARS-CoV-2 virus, like the SARS-CoV-1 counterpart, binds Angiotensin-Converting Enzyme 2 (ACE2), but with much higher affinity and faster binding kinetics (9). Before binding to the ACE2 receptor, structural analysis of the S1 trimer shows that only one of the three RBD domains in the trimeric structure is in the "up" conformation. This is an unstable and transient state that passes between trimeric subunits but is nevertheless an exposed state to be targeted for neutralizing antibody therapy (10). Polyclonal antibodies to the RBD of the SARS-CoV-2 S1 subunit have been shown to inhibit interaction with the ACE2 receptor, confirming RBD as an attractive target for vaccinations or antiviral therapy (11). There is also promising work showing that the RBD may be used to detect presence of neutralizing antibodies present in a patient's bloodstream, consistent with developed immunity after exposure to the SARS-CoV-2 virus (12). Lastly, it has been demonstrated the S Protein can invade host cells through the CD147/EMMPRIN receptor and mediate membrane fusion (13, 14).

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 3 confirmed species: Human, Mouse, African Green Monkey.

We have publications tested in 3 applications: IHC, In Vivo, Western Blot.

Showing Publications 1 - 6 of 6.

Publications using MAB105403	Applications	Species
Qing, E;Gallagher, T; Adaptive variations in SARS-CoV-2 spike proteins: effects on distinct virus-cell entry stages mBio 2023-06-29 [PMID: 37382441] (Western Blot)	Western Blot
Mitchell, A;Yu, C;Zhao, X;Pearmain, L;Shah, R;Hanley, KP;Felton, T;Wang, T; Rapid Generation of Pulmonary Organoids from Induced Pluripotent Stem Cells by Co-Culturing Endodermal and Mesodermal Progenitors for Pulmonary Disease Modelling Biomedicines 2023-05-18 [PMID: 37239147] (IHC, Human)	IHC	Human
MA Erickson, AF Logsdon, EM Rhea, KM Hansen, SJ Holden, WA Banks, JL Smith, C German, SA Farr, JE Morley, RR Weaver, AJ Hirsch, A Kovac, E Kontsekova, KK Baumann, MA Omer, J Raber Blood-brain barrier penetration of non-replicating SARS-CoV-2 and S1 Variants of Concern induce neuroinflammation which is accentuated in a mouse model of Alzheimer's disease Brain, Behavior, and Immunity, 2023-01-20;0(0):. 2023-01-20 [PMID: 36682515] (In Vivo, Mouse)	In Vivo	Mouse
Jeffrey Arrindell, Perla Abou Atmeh, Laurie Jayet, Youssouf Sereme, Jean-Louis Mege, Benoit Desnues Vimentin is an important ACE2 co-receptor for SARS-CoV-2 in epithelial cells iScience 11/18/2022 [PMID: 36338433]
N Iwata-Yosh, M Kakizaki, N Shiwa-Sudo, T Okura, M Tahara, S Fukushi, K Maeda, M Kawase, H Asanuma, Y Tomita, I Takayama, S Matsuyama, K Shirato, T Suzuki, N Nagata, M Takeda Essential role of TMPRSS2 in SARS-CoV-2 infection in murine airways Nature Communications, 2022-10-15;13(1):6100. 2022-10-15 [PMID: 36243815] (Western Blot, African Green Monkey)	Western Blot	African Green Monkey
B Meng, R Datir, J Choi, CITIID-NIH, JR Bradley, KGC Smith, JH Lee, RK Gupta SARS-CoV-2 spike N-terminal domain modulates TMPRSS2-dependent viral entry and fusogenicity Cell Reports, 2022-08-03;40(7):111220. 2022-08-03 [PMID: 35963244] (Western Blot, Human)	Western Blot	Human

Array MAB105403

• SARS-CoV-2 Spike S1 Protein Antibodies
• SARS-CoV-2 Spike S1 Protein Proteins and Enzymes